At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 52 enrolled
Drug / intervention
Lanreotide Autogeldrug
Likely dose
Lanreotide Autogel 120mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An International, Multicentric, Prospective, Open Label Study to Assess the Efficacy and Safety of Lanreotide Autogel 120 MG Associated to Standard of Care in the Treatment of Clinical Symptoms Associated With Inoperable Malignant Intestinal Obstruction
In Brief
A Phase 2 clinical trial evaluating Lanreotide Autogel for Intestinal Obstruction. Completed, enrolled 52 participants across 17 sites.
Detailed Summary
To assess the efficacy of Lanreotide Autogel 120 mg for the relief of vomiting due to inoperable malignant intestinal obstruction in patients without nasogastric tube (NGT) and to assess the efficacy of lanreotide Autogel 120 mg on removal of nasogastric tube without the recurrence of vomiting in patients with an inoperable malignant intestinal obstruction with a nasogastric tube.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIntestinal Obstruction
CountriesBelgium
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedOct 2014
Enrollment StartNov 2014
Primary CompletionNov 2017
TodayJul 2026
First PostedOct 27, 2014
Enrollment StartNov 19, 2014
Primary CompletionNov 9, 2017
TodayJul 2, 2026
Enrollment to primary: 3.0 yearsPosted 11.7 years ago
Interventions
Lanreotide Autogeldrug
120mg administered via deep subcutaneous injection at Day 0 and Day 28.